A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
for Locally Advanced Solid Tumors
Drug: Repotrectinib
49 locations incl. Duarte
Sponsor: Turning Point Therapeutics, Inc.
Sex: All·Age: 12+
Code: NCT03093116·Phase 1, Phase 2·Recruiting